Trade Sino Biopharmaceutical Limited - 1177 CFD
Add to favourite- Summary
- Historical Data
Spread | 0.04 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023333% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001415% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | HKD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | Hong Kong | ||||||||
Commission on trade | 0% |
Prev. Close | 3.08 |
Open | 3.1 |
1-Year Change | 8.39% |
Day's Range | 3.08 - 3.16 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 11, 2024 | 3.12 | 0.06 | 1.96% | 3.06 | 3.16 | 3.06 |
Sep 10, 2024 | 3.08 | -0.02 | -0.65% | 3.10 | 3.10 | 3.04 |
Sep 9, 2024 | 3.10 | 0.00 | 0.00% | 3.10 | 3.16 | 3.06 |
Sep 5, 2024 | 3.14 | 0.06 | 1.95% | 3.08 | 3.14 | 3.08 |
Sep 4, 2024 | 3.08 | 0.02 | 0.65% | 3.06 | 3.10 | 3.04 |
Sep 3, 2024 | 3.10 | 0.02 | 0.65% | 3.08 | 3.16 | 3.08 |
Sep 2, 2024 | 3.10 | -0.08 | -2.52% | 3.18 | 3.20 | 3.08 |
Aug 30, 2024 | 3.20 | 0.00 | 0.00% | 3.20 | 3.24 | 3.16 |
Aug 29, 2024 | 3.20 | 0.06 | 1.91% | 3.14 | 3.22 | 3.12 |
Aug 28, 2024 | 3.14 | 0.00 | 0.00% | 3.14 | 3.16 | 3.10 |
Aug 27, 2024 | 3.12 | 0.04 | 1.30% | 3.08 | 3.14 | 3.06 |
Aug 26, 2024 | 3.10 | 0.00 | 0.00% | 3.10 | 3.16 | 3.06 |
Aug 23, 2024 | 3.12 | -0.06 | -1.89% | 3.18 | 3.20 | 3.08 |
Aug 22, 2024 | 3.18 | -0.04 | -1.24% | 3.22 | 3.24 | 3.14 |
Aug 21, 2024 | 3.20 | 0.02 | 0.63% | 3.18 | 3.22 | 3.14 |
Aug 20, 2024 | 3.24 | -0.02 | -0.61% | 3.26 | 3.30 | 3.22 |
Aug 19, 2024 | 3.22 | -0.06 | -1.83% | 3.28 | 3.28 | 3.20 |
Aug 16, 2024 | 3.26 | 0.08 | 2.52% | 3.18 | 3.34 | 3.14 |
Aug 15, 2024 | 3.16 | 0.18 | 6.04% | 2.98 | 3.18 | 2.98 |
Aug 14, 2024 | 2.98 | -0.10 | -3.25% | 3.08 | 3.12 | 2.92 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sino Biopharmeceutical Company profile
Sino Biopharmaceutical Limited, researches, develops, manufactures, and sells Chinese medicines and chemical medicines in Hong Kong, Mainland China, and internationally. The company operates in Modernized Chinese Medicines and Chemical Medicines, Investment, and Others segments. Its principal products include hepatitis medicines, such as Runzhong dispersible tablets, Tianqingganmei injections, Tianqingganping enteric capsules, Tianding tablets, Mingzheng capsules, and Ganlixin injections and capsules; and cardio-cerebral medicines comprising Kaishi injections, Yilunping and Tuotuo tablets, Tianqingning injections, and Beraprost Sodium tablets; and oncology medicines consisting of Zhiruo, Saiweijian, Tianqingyitai, and Qingweike injections, as well as Shoufu and Yinishu tablets, and Gelike capsules. The company's principal products also include Analgesic medicines, such as Kaifen injections and Zepusi Flurbiprofen Cataplasms; Orthopedic medicines, which comprise New Ossified Triol capsules and Jiuli tablets; anti-infectious medicines, including Tiance injections and Tianjie tablets; parenteral nutritious medicines, such as Xinhaineng and Fenghaineng fructose injections; respiratory system medicines, including Tianqingsule inhalation powder and Chia Tai Suke tablets; and anorectal medicines comprising Aisuping injections and Getai tablets. In addition, it develops medicines for liver, tumor, cardio-cerebral, analgesia, respiratory system, and orthopedic diseases; engages in the retail and distribution of pharmaceutical products; provides medical management consultancy services; and manufactures, sells, and distributes health food products, as well as is involved in optometry for optical glasses and sale of ophthalmic products. Further, the company provides research and development, medical technology development, and outpatient and surgical procedure services. The company was incorporated in 2000 and is headquartered in Wanchai, Hong Kong.Industry: | Pharmaceuticals (NEC) |
湾仔港湾道1号会展广场辨公大楼41楼09室
HK
News
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com